Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.
IPO Year: 2020
Exchange: NYSE
Website: https://www.gelesis.com
4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)
4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)
4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)
4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)
4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)
4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)
4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)
4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)
4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)
4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)
8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)
CT ORDER - GELESIS HOLDINGS, INC. (0001805087) (Filer)
8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)
SC 13E3/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)
PRER14A - GELESIS HOLDINGS, INC. (0001805087) (Filer)
8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)
SC 13E3/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)
PRER14A - GELESIS HOLDINGS, INC. (0001805087) (Filer)
8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)
8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)